CN108410892B - 降低由pd-l1诱导的免疫耐受性 - Google Patents

降低由pd-l1诱导的免疫耐受性 Download PDF

Info

Publication number
CN108410892B
CN108410892B CN201810281004.XA CN201810281004A CN108410892B CN 108410892 B CN108410892 B CN 108410892B CN 201810281004 A CN201810281004 A CN 201810281004A CN 108410892 B CN108410892 B CN 108410892B
Authority
CN
China
Prior art keywords
nucleic acid
cells
acid sequence
cell
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810281004.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN108410892A (zh
Inventor
吴昭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Xuxu Technology Co ltd
Original Assignee
Sidansai Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidansai Biotechnology Co Ltd filed Critical Sidansai Biotechnology Co Ltd
Publication of CN108410892A publication Critical patent/CN108410892A/zh
Application granted granted Critical
Publication of CN108410892B publication Critical patent/CN108410892B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
CN201810281004.XA 2015-03-02 2016-03-01 降低由pd-l1诱导的免疫耐受性 Active CN108410892B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562126804P 2015-03-02 2015-03-02
US62/126,804 2015-03-02
CN201680002926.1A CN107073138B (zh) 2015-03-02 2016-03-01 降低由pd-l1诱导的免疫耐受性

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680002926.1A Division CN107073138B (zh) 2015-03-02 2016-03-01 降低由pd-l1诱导的免疫耐受性

Publications (2)

Publication Number Publication Date
CN108410892A CN108410892A (zh) 2018-08-17
CN108410892B true CN108410892B (zh) 2021-05-28

Family

ID=56848306

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810281004.XA Active CN108410892B (zh) 2015-03-02 2016-03-01 降低由pd-l1诱导的免疫耐受性
CN201680002926.1A Active CN107073138B (zh) 2015-03-02 2016-03-01 降低由pd-l1诱导的免疫耐受性

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680002926.1A Active CN107073138B (zh) 2015-03-02 2016-03-01 降低由pd-l1诱导的免疫耐受性

Country Status (11)

Country Link
US (4) US9572837B2 (cg-RX-API-DMAC7.html)
EP (2) EP3089761B1 (cg-RX-API-DMAC7.html)
JP (2) JP6336684B2 (cg-RX-API-DMAC7.html)
KR (1) KR102133857B1 (cg-RX-API-DMAC7.html)
CN (2) CN108410892B (cg-RX-API-DMAC7.html)
AU (1) AU2016228080B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017018770A2 (cg-RX-API-DMAC7.html)
CA (1) CA2976684C (cg-RX-API-DMAC7.html)
RU (1) RU2688692C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201706947TA (cg-RX-API-DMAC7.html)
WO (1) WO2016138846A1 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
HRP20220890T1 (hr) 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
BR112017018770A2 (pt) 2015-03-02 2018-04-17 Innovative Cellular Therapeutics CO., LTD. redução da tolerância imunológica induzida por pd-l1
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US11242375B2 (en) 2015-09-04 2022-02-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
CN109072194B (zh) 2015-12-09 2022-12-27 纪念斯隆-凯特林癌症中心 免疫细胞组合物及其使用方法
US11365237B2 (en) * 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
US10654934B2 (en) 2016-04-01 2020-05-19 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
CN113082201B (zh) 2016-04-01 2024-07-05 上海斯丹赛生物技术有限公司 刺激t细胞介导的对表达抗原的细胞群的免疫应答的方法
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3034691A1 (en) 2016-08-30 2018-03-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use for treating viral and other infections
WO2018064921A1 (en) * 2016-10-06 2018-04-12 Innovative Cellular Therapeutics CO., LTD. Use of chimeric antigen receptor modified cells to treat cancer
BR112019007100A2 (pt) 2016-10-07 2019-06-25 Tcr2 Therapeutics Inc composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
CN118581046A (zh) 2016-11-22 2024-09-03 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
CN108148862B (zh) * 2016-12-05 2019-03-08 上海优卡迪生物医药科技有限公司 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
WO2018104473A1 (en) 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
AU2018231190B2 (en) * 2017-03-08 2023-05-25 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
CA3071282A1 (en) 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
JP2020536531A (ja) * 2017-09-26 2020-12-17 ロングウッド ユニバーシティーLongwood University 免疫療法としてのpd1特異的キメラ抗原受容体
CN109836493A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向cd19的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
US10561686B2 (en) * 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
AU2019218729B2 (en) 2018-02-06 2025-12-04 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific CARs exhibiting optimal T cell function against FL-PLE labelled tumors
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Car t細胞療法のための配列決定法
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
JP7584299B2 (ja) 2018-05-23 2024-11-15 ナショナル ユニバーシティ オブ シンガポール T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現
US12240915B2 (en) 2018-08-30 2025-03-04 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
WO2020086989A1 (en) * 2018-10-25 2020-04-30 Innovative Cellular Therapeutics CO., LTD. Increase or maintaining t-cell subpopulations in adoptive t-cell therapy
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
WO2020116686A1 (ko) * 2018-12-06 2020-06-11 고려대학교 산학협력단 인간 항-antxr 키메라 항원 수용체 및 이의 용도
CN109971842A (zh) * 2019-02-15 2019-07-05 成都美杰赛尔生物科技有限公司 一种检测CRISPR-Cas9脱靶效应的方法
US20220088074A1 (en) * 2019-02-21 2022-03-24 Regents Of The University Of Minnesota Genetically modified gamma delta t cells and methods of making and using
IL285941B1 (en) * 2019-03-01 2026-08-01 Allogene Therapeutics Inc Cytokine chemoreceptors bearing the PD-1 ECTODOMAIN
JP2022531814A (ja) * 2019-03-12 2022-07-12 イノベイティブ セルラー セラピューティクス ホールディングス,エルティディ 改変細胞の増幅およびその応用
US11739136B2 (en) * 2019-03-18 2023-08-29 Innovative Cellular Therapeutics Holdings, Ltd. Inducible dominant negative PD-1 and uses in adoptive cell therapy
CN109868263A (zh) * 2019-03-29 2019-06-11 深圳精准医疗科技有限公司 重组单纯疱疹病毒及其制备方法和应用、重组载体的构建方法及其应用
SG11202112676VA (en) * 2019-05-16 2021-12-30 Memorial Sloan Kettering Cancer Center Mesothelin cars and uses thereof
CN110423767A (zh) * 2019-07-12 2019-11-08 华东师范大学 表达可溶性pd-1的嵌合抗原受体car基因及应用
US12702708B2 (en) 2019-08-21 2026-08-11 Innovative Cellular Therapeutics Holdings, Ltd. Presenting cell and use thereof in cell therapy
CN110592140A (zh) * 2019-09-30 2019-12-20 王清路 Pd-1基因缺陷型pd-1-cart细胞制剂的制法
US20210137983A1 (en) * 2019-11-08 2021-05-13 Innovative Cellular Therapeutics Holdings, Ltd. Nk cell expansion and uses thereof
CN118147081A (zh) * 2019-11-26 2024-06-07 南克维斯特公司 原代nk car构建体和方法
IL295063A (en) 2020-02-04 2022-09-01 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Chimeric antigen receptors (car) against dinitrophenol
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
JP7198302B2 (ja) * 2021-03-08 2022-12-28 一般財団法人 化学物質評価研究機構 Pd-1を介した免疫チェックポイント阻害剤の生物活性試験法
EP4215245A1 (en) 2022-01-19 2023-07-26 Innovative Cellular Therapeutics Holdings, Ltd. Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment
WO2025184170A1 (en) * 2024-02-27 2025-09-04 Overt Bio, Inc. Methods and compositions for improving t cell function in an immunosuppressive environment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114233A (zh) * 2011-07-29 2014-10-22 宾夕法尼亚大学董事会 转换共刺激受体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
EP1425421A2 (en) * 2001-09-07 2004-06-09 Everygene AB Polymorphisms of pd-1
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP6074435B2 (ja) * 2011-10-26 2017-02-01 ナショナル キャンサー センター 変異ctla4遺伝子移入t細胞及びこれを含む抗がん免疫治療用組成物
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
SG10201806573TA (en) * 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
WO2014059173A2 (en) * 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
IL298125A (en) * 2013-02-26 2023-01-01 Memorial Sloan Kettering Cancer Center Preparations and methods for immunotherapy
ES2769574T3 (es) * 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
WO2014161509A1 (en) 2013-04-05 2014-10-09 The University Of Hong Kong Novel pd1 isoforms, and uses thereof for potentiating immune responses
KR102164455B1 (ko) 2013-05-08 2020-10-13 삼성전자주식회사 콘텐트 제공 방법, 콘텐트 제공 장치 및 그 콘텐트 제공 시스템
US10260038B2 (en) * 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
WO2015142661A1 (en) 2014-03-15 2015-09-24 Novartis Ag Regulatable chimeric antigen receptor
CN122399016A (zh) 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
EP3177640B1 (en) * 2014-08-08 2020-05-06 The Board of Trustees of the Leland Stanford Junior University High affinity pd-1 agents and methods of use
BR112017018770A2 (pt) 2015-03-02 2018-04-17 Innovative Cellular Therapeutics CO., LTD. redução da tolerância imunológica induzida por pd-l1
US10493139B2 (en) 2015-07-24 2019-12-03 Innovative Cellular Therapeutics CO., LTD. Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor
US11242375B2 (en) 2015-09-04 2022-02-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
CN109072194B (zh) 2015-12-09 2022-12-27 纪念斯隆-凯特林癌症中心 免疫细胞组合物及其使用方法
CA3088161A1 (en) 2018-01-11 2019-07-18 Innovative Cellular Therapeutics Inc. Modified cell expansion and uses thereof
WO2020086989A1 (en) 2018-10-25 2020-04-30 Innovative Cellular Therapeutics CO., LTD. Increase or maintaining t-cell subpopulations in adoptive t-cell therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104114233A (zh) * 2011-07-29 2014-10-22 宾夕法尼亚大学董事会 转换共刺激受体

Also Published As

Publication number Publication date
KR20170124576A (ko) 2017-11-10
CN107073138B (zh) 2018-06-29
EP3549612A1 (en) 2019-10-09
EP3549612B1 (en) 2025-04-30
US20160256488A1 (en) 2016-09-08
AU2016228080B2 (en) 2020-11-12
EP3089761A4 (en) 2017-05-10
CA2976684A1 (en) 2016-09-09
AU2016228080A1 (en) 2017-09-07
RU2017130985A (ru) 2019-03-04
JP2018508539A (ja) 2018-03-29
JP6336684B2 (ja) 2018-06-06
CA2976684C (en) 2024-03-05
CN107073138A (zh) 2017-08-18
US20170096638A1 (en) 2017-04-06
KR102133857B1 (ko) 2020-07-20
US20210079349A1 (en) 2021-03-18
CN108410892A (zh) 2018-08-17
US20190316086A1 (en) 2019-10-17
JP2018064568A (ja) 2018-04-26
EP3089761B1 (en) 2019-06-12
US10619136B2 (en) 2020-04-14
US9572837B2 (en) 2017-02-21
RU2017130985A3 (cg-RX-API-DMAC7.html) 2019-03-04
BR112017018770A2 (pt) 2018-04-17
SG11201706947TA (en) 2017-09-28
EP3089761A1 (en) 2016-11-09
US11932873B2 (en) 2024-03-19
WO2016138846A1 (en) 2016-09-09
RU2688692C2 (ru) 2019-05-22
US10865382B2 (en) 2020-12-15
JP6767347B2 (ja) 2020-10-14

Similar Documents

Publication Publication Date Title
US11932873B2 (en) Reducing immune tolerance induced by PD-L1
EP3436059B1 (en) Use of chimeric antigen receptor modified cells to treat cancer
US11566223B2 (en) Chimeric antigen receptor cell preparation and uses thereof
US10561686B2 (en) Modified cell expansion and uses thereof
US11235004B2 (en) Lymphocyte cell lines and uses thereof
US20180223255A1 (en) Activation and Expansion of T Cells
US11773384B2 (en) Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells
CN110257338B (zh) 嵌合细胞因子受体
US20210379149A1 (en) Increasing or Maintaining T-Cell Subpopulations in Adoptive T-Cell Therapy
CN110540997A (zh) 靶向bcma嵌合抗原受体、核酸序列、载体及应用
HK1228783A1 (en) Reducing immune tolerance induced by pd l1
HK1228783B (en) Reducing immune tolerance induced by pd l1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20211201

Address after: 201203 floor 3, building 1, No. 6055, Jinhai Road, Fengxian District, Shanghai

Patentee after: Shanghai Xuxu Technology Co.,Ltd.

Address before: 201203 Room 201, building 4, 998 HaLei Road, Pudong New Area, Shanghai

Patentee before: SHANGHAI SIDANSAI BIOTECHNOLOGY CO.,LTD.

TR01 Transfer of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Decreased immune tolerance induced by PD-L1

Effective date of registration: 20220725

Granted publication date: 20210528

Pledgee: Industrial Bank Co.,Ltd. Shanghai Changning sub branch

Pledgor: Shanghai Xuxu Technology Co.,Ltd.

Registration number: Y2022310000143

PE01 Entry into force of the registration of the contract for pledge of patent right
CP03 Change of name, title or address

Address after: No. 29, 1st Floor, Building 2, No. 198 Peninsula Middle Road, Dipu Street, Anji County, Huzhou City, Zhejiang Province, 313300 (self declared)

Patentee after: Zhejiang Xuxu Technology Co.,Ltd.

Address before: 201203 floor 3, building 1, No. 6055, Jinhai Road, Fengxian District, Shanghai

Patentee before: Shanghai Xuxu Technology Co.,Ltd.

CP03 Change of name, title or address
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20231123

Granted publication date: 20210528

Pledgee: Industrial Bank Co.,Ltd. Shanghai Changning sub branch

Pledgor: Shanghai Xuxu Technology Co.,Ltd.

Registration number: Y2022310000143

PC01 Cancellation of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Decreased immune tolerance induced by PD-L1

Granted publication date: 20210528

Pledgee: Agricultural Bank of China Limited Shanghai Fengxian Branch

Pledgor: Zhejiang Xuxu Technology Co.,Ltd.

Registration number: Y2025980042572

PE01 Entry into force of the registration of the contract for pledge of patent right